NCT01240642View on ClinicalTrials.gov

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

PHASE1TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

December 31, 2010

Conditions
Metastatic Cancer With Impaired Renal FunctionMetastatic Cancer With Normal Renal Function
Interventions
DRUG

ASA404

Trial Locations (4)

Unknown

Novartis Investigative Site, Charleroi

Novartis Investigative Site, Jette

Novartis Investigative Site, Saint-Lambert

Novartis Investigative Site, Wilrijk

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY